𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson’s disease

✍ Scribed by V. G. Rasmussen; S. H. Poulsen; E. Dupont; K. Østergaard; G. Safikhany; H. Egeblad

Book ID
108862417
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
120 KB
Volume
0
Category
Article
ISSN
0954-6820

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Meta-analysis of heart valve abnormaliti
Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists
✍ Gregor Simonis; Joerg T. Fuhrmann; Ruth H. Strasser 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

## Abstract Valvular heart disease in patients being treated with ergot‐derivative dopamine agonists (Ergot‐DA) for Parkinson's disease has been reported to occur as a consequence of serotonine receptor stimulation. Goal of this analysis was to estimate the incidence of those changes from recently

Valvular heart disease in Parkinson's di
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader-blinded monocenter echocardiography study
✍ Susann Junghanns; Joerg T. Fuhrmann; Gregor Simonis; Christian Oelwein; Rainer K 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

## Abstract Fibrotic valvular heart disease (VHD) has been reported in association with ergot dopamine agonists (DAs), but the current database is insufficient regarding clinical relevance and comparison to data on non‐ergot DAs. We evaluated the effects of four DAs (pergolide, cabergoline, ropinir

Antiparkinsonian activity of a non-ergot
Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease
✍ Dr. W. Poewe; G. Luef; B. Kleedorfer; M. Emre 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB

## Abstract Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205‐502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L‐DOPA. CV 205‐502,